INSTITUTE FOR MEDICAL TECHNOLOGY ASSESSMENT BV

Their core work

iMTA is a Rotterdam-based health economics consultancy specializing in medical technology assessment, cost-effectiveness analysis, and health policy modelling. They evaluate whether medical interventions deliver value for money by comparing costs and outcomes across treatments, healthcare systems, and patient populations. Their work directly informs reimbursement decisions, clinical guidelines, and pharmaceutical pricing strategies across Europe. They bring economic modelling and decision-analytic expertise to multi-country research consortia studying chronic disease management and personalized medicine.

What they specialise in

How they've shifted over time

With only three projects starting between 2018 and 2019, the timeline is too short to identify a dramatic evolution. However, a clear thematic progression is visible: from broad cost-outcome analysis of medical technologies (COMED, where they served as a third party) toward more specialized health economic modelling for personalized medicine (HEcoPerMed). Their trajectory suggests a move from traditional HTA methods toward forward-looking simulation and future-studies approaches tailored to emerging precision medicine frameworks.

Moving toward economic evaluation of personalized and precision medicine, positioning them at the intersection of HTA and individualized treatment decision-making.

How they like to work

iMTA consistently operates as a specialist contributor rather than a project leader — they have never coordinated a project and participated once as a third party. They work within medium-to-large consortia, connecting with 16 unique partners across 10 countries from just three projects. This pattern indicates they are brought in specifically for their health economics and modelling expertise, functioning as a trusted methodological partner rather than a project driver.

Despite a small project portfolio, iMTA has built a broad European network spanning 16 partners across 10 countries, reflecting the multi-country nature of health system comparison studies. Their Rotterdam base and Dutch affiliation place them centrally within European health policy networks.

What sets them apart

iMTA occupies a niche as a private-sector health economics consultancy that bridges academic rigour with practical policy impact — unusual in a landscape dominated by university-embedded HTA groups. Their ability to model costs and outcomes across different healthcare systems makes them a valuable partner for any consortium that needs to demonstrate economic viability or inform reimbursement policy. For coordinators building health-related proposals, they offer dedicated HTA work package capacity without the overhead of engaging a full university department.

Highlights from their portfolio

• COMPAR-EU
  Largest funding share (EUR 776,600) — ambitious multi-country comparison of self-management interventions across four chronic diseases.
• HEcoPerMed
  Positions iMTA at the frontier of personalized medicine economics, linking health policy modelling with the ICPerMed initiative.